NCT07030686 Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors
| NCT ID | NCT07030686 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Survivorship |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-03-19 |
| Primary Completion | 2027-03-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2020-03-19 with a primary completion date of 2027-03-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This protocol is a retrospective study using observational data to conduct a target trial emulation to examine the association of exercise on cancer specific endpoints and other clinical outcomes in cancer survivors.
Eligibility Criteria
Inclusion Criteria: Target trial (ideal RCT) * Adult (≥18 years of age) patients with history of primary invasive cancer under surveillance at Memorial Sloan Kettering Cancer Center (MSK). * Completion of an exercise survey (baseline) as part of MSK Cancer Survivorship Program and completion of a historical survey in the MSK Cancer Survivorship Program 9-15 months (time th) prior reporting non-exercising status \[i.e., reporting \<10 metabolic equivalent-hours per week (MET-h/week)\]. Patients completing an additional exercise survey between th and baseline are excluded. * No evidence of recurrent or metastatic disease in the 15 months prior to the baseline exercise assessment * Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of the historical exercise survey in a MSK Cancer Survivorship Program. Adjuvant hormonal therapy is permitted at any time. * Undergoing surveillance in the Cancer Survivorship Program at MSK Emulation using observational data * Adult (≥18 years of age) cancer survivors under surveillance at Memorial Sloan Kettering Cancer Center (MSK) between 2011 and 2023. * Assessment of self-reported exercise status via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake (baseline assessment). * Non-exercising (i.e., reporting \<5 MET-h/week) via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake 9-15 months prior to the baseline exercise assessment (historical exercise survey). * Documented history of the following absolute contraindications to moderate-intensity exercise at any time prior to the baseline exercise assessment, assessed using the Elixhauser ICD codes: Congestive heart failure, valvular disease, chronic pulmonary disease, or renal failure. * No evidence of recurrent or metastatic disease via radiological or pathological in EMR in the 15 months prior to the baseline exercise assessment. * Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of historical exercise survey (i.e., at least 3 months prior to t-1) as part of MSK Cancer Survivorship Program standard intake. Adjuvant endocrine therapy is permitted.
Contact & Investigator
Jessica Scott, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07030686 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Survivorship. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07030686 currently recruiting?
Yes, NCT07030686 is actively recruiting participants. Contact the research team at scottj1@mskcc.org for enrollment information.
Where is the NCT07030686 trial being conducted?
This trial is being conducted at Duarte, United States, Los Angeles, United States, New York, United States, New York, United States.
Who is sponsoring the NCT07030686 clinical trial?
NCT07030686 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Jessica Scott, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 1,000 participants.